



Press Release |

IBA announces its new conceptual Two-Step Particle Therapy System at ASTRO

For immediate release, November 6, 2006

Louvain-la-Neuve, Belgium, November 6, 2006 – IBA (Ion Beam Applications S.A.: Reuters IOBAAt.BR and Bloomberg IBAB.BB) unveiled today its new concept of Two-Step Particle Therapy System. The announcement was made at the 48th Annual Meeting of ASTRO (American Society for Therapeutic Radiology and Oncology) in Philadelphia, PA, USA.

The Two-Step Particle Therapy System will enable a hospital to begin administering Proton Therapy and gradually bring Carbon and Light Ion Therapy on-line within the same facility. This by using a new 400 MeV (Million Electron Volts) cyclotron for accelerating Carbon and other Light Ions in a clinical Particle Therapy environment.

Particle Therapy is the generic name encompassing radiation therapy of cancerous cells using either Protons or Ions such as Carbon 6. Proton Therapy is the most advanced clinical modality for treating cancer with radiation as it causes less damage to healthy tissue and deposit the majority of the destructive energy to the cancerous cells. Carbon Therapy is a promising modality because of its excellent dose localization and high biological effect on tumor. Carbon Therapy is able to treat deep-seated tumors that are often radio-resistant.

“At this stage, all major uncertainties have been cleared, and several major hospitals have expressed an interest in the IBA approach and expanded clinical capabilities. While IBA is well-positioned to deliver it, there remain regulatory and reimbursement decisions yet to be taken,” said Pierre Mottet, Chief Executive Officer of IBA. “Our unique concept of the two-step approach helps mitigate these risks, allowing an institution to get started, gain experience and financial viability with Proton Therapy as the first step, and add Carbon Therapy capability some years later – when regulatory requirements have been met and appropriate reimbursement established.”


An ideal radiotherapy arsenal for cancer would include high-energy X-rays, Protons, and Carbon – and possibly other Light Ions. Clinicians debate over the “ideal therapeutic particle”, but most agree on the proven benefits of Protons and Carbon ions. The IBA Two-Step PT System design includes a unique ion source switching system which allows multiple ion species to be utilized, changing sources in under one minute. At least eight different ion species are compatible with the IBA system, giving physicians the possibility to administer some potentially exotic Particle Therapy regimens. The system

Press Release |

also features a new isocentric gantry capable of delivering both Protons and Light Ions, already possible with fixed-beam treatment rooms.

The IBA approach claims to enable those interested in moving toward Light Ion Particle Therapy to benefit from a faster, lower-risk start-up with well-established IBA Proton components. This reduces the possibility of delay for start-up of the facility if there were still to be a lack of FDA clearance of Light Ion therapy. Provided that the therapy is cleared, the IBA Two-Step PT configuration will allow simultaneous treatments in two treatment rooms, and with two accelerators operating in parallel – a degree of redundancy and ostensibly higher reliability while maintaining the simplicity and proven operational advantages of the current IBA cyclotron.

IBA TWO-STEP PARTICLE THERAPY SYSTEM



Note: Some features mentioned will be subject to reviews by the Competent Authorities (FDA, European Notified Bodies, ...) before they will be commercially available.



Press Release |

ABOUT IBA

IBA delivers solutions of a unique precision in the fields of **cancer diagnosis and therapy**. The company also offers sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to the BelMid index.

Website: <http://www.iba-worldwide.com>.

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Phone: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com

ASTRO On-site Contact – Philadelphia – November 5 to 8

IBA – Booth #651

Bernt Nordin
Executive Vice President, Sales and Marketing
Phone: +1.904.400.0445
bernt.nordin@iba-group.com